Israeli company on verge of breakthrough in celiac drug development
TEV '408 succeeded in blocking intestinal damage from gluten exposure, positioning Teva for a potentially lucrative entry into a market ...
Tag: celiac disease
TEV '408 succeeded in blocking intestinal damage from gluten exposure, positioning Teva for a potentially lucrative entry into a market ...